Differences between HCV RNA assays might influence treatment decisions.
Concordance of 3 real-time PCR-based HCV RNA assays was tested.
Plasma samples from Phase III simeprevir/PegIFN/RBV studies (HCV genotype 1 and 4) were used.
Inter-assay concordance was generally good, except in low viremic samples at early time points.
An HCV RNA threshold <25 IU/mL was more assay-independent than RNA undetectability.